Spectrum News: After delay, AntiOD device ready for deployment
Narcan-dispensing device, created at UC, to be implemented in two Ohio counties
Earlier this year, the University of Cincinnati launched a project aimed at educating the public about opioid overdoses and how to help while creating access to the overdose reversal medication naloxone, or Narcan. AntiOD is a smart dispenser that contains everything needed to start aiding an overdose victim while waiting for emergency help to arrive.
After a series of redesigns, plus work and research in the community, AntiOD is ready to be implemented in Ohio's Summit and Cuyahoga counties, according to Claudia Rebola, associate dean for research and associate professor in UC's College of Design, Architecture, Art, and Planning.
Rebola and one of her graduate students in DAAP's Myron E. Ullman School of Design, Ryan Norton, spoke to Spectrum News about the continuation and implementation of AntiOD. Read more and watch the interview.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.
Combination immunotherapy helps overcome melanoma treatment resistance
November 10, 2025
MSN highlighted research led by the University of Cincinnati Cancer Center's Trisha Wise-Draper showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.